These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9081298)

  • 21. [Plant-based production of recombinant cytokines].
    Góra-Sochacka A; Redkiewicz P; Napiórkowska B; Sirko A
    Postepy Biochem; 2009; 55(1):85-94. PubMed ID: 19514469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New role for tobacco--production of biopharmaceuticals].
    Budzianowski J
    Przegl Lek; 2009; 66(10):894-7. PubMed ID: 20301965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction to gene technology.
    Ritschel WA; Forusz H
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):453-67. PubMed ID: 7885071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient expression systems for plant-derived biopharmaceuticals.
    Komarova TV; Baschieri S; Donini M; Marusic C; Benvenuto E; Dorokhov YL
    Expert Rev Vaccines; 2010 Aug; 9(8):859-76. PubMed ID: 20673010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnifection--a new platform for expressing recombinant vaccines in plants.
    Gleba Y; Klimyuk V; Marillonnet S
    Vaccine; 2005 Mar; 23(17-18):2042-8. PubMed ID: 15755568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Manufacturing of recombinant therapeutic proteins in microbial systems.
    Graumann K; Premstaller A
    Biotechnol J; 2006 Feb; 1(2):164-86. PubMed ID: 16892246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current achievements in the production of complex biopharmaceuticals with moss bioreactors.
    Decker EL; Reski R
    Bioprocess Biosyst Eng; 2008 Jan; 31(1):3-9. PubMed ID: 17701058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality assessment of recombinant proteins produced in plants.
    Medrano G; Dolan MC; Condori J; Radin DN; Cramer CL
    Methods Mol Biol; 2012; 824():535-64. PubMed ID: 22160919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: current status and perspectives.
    Rosales-Mendoza S; Paz-Maldonado LM; Soria-Guerra RE
    Plant Cell Rep; 2012 Mar; 31(3):479-94. PubMed ID: 22080228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining and characterizing the late-stage biopharmaceutical pipeline.
    Nagle PC; Lugo TF; Nicita CA
    Am J Manag Care; 2003 Oct; 9(6 Suppl):S124-35. PubMed ID: 14577717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seed-based expression systems for plant molecular farming.
    Boothe J; Nykiforuk C; Shen Y; Zaplachinski S; Szarka S; Kuhlman P; Murray E; Morck D; Moloney MM
    Plant Biotechnol J; 2010 Jun; 8(5):588-606. PubMed ID: 20500681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purification.
    Pujol M; Ramírez NI; Ayala M; Gavilondo JV; Valdés R; Rodríguez M; Brito J; Padilla S; Gómez L; Reyes B; Peral R; Pérez M; Marcelo JL; Milá L; Sánchez RF; Páez R; Cremata JA; Enríquez G; Mendoza O; Ortega M; Borroto C
    Vaccine; 2005 Mar; 23(15):1833-7. PubMed ID: 15734051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Industry and regulatory experience of the glycosylation of monoclonal antibodies.
    Read EK; Park JT; Brorson KA
    Biotechnol Appl Biochem; 2011; 58(4):213-9. PubMed ID: 21838794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hybrid and disposable facilities for manufacturing of biopharmaceuticals: pros and cons.
    Ravisé A; Cameau E; De Abreu G; Pralong A
    Adv Biochem Eng Biotechnol; 2009; 115():185-219. PubMed ID: 19623478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moss bioreactors producing improved biopharmaceuticals.
    Decker EL; Reski R
    Curr Opin Biotechnol; 2007 Oct; 18(5):393-8. PubMed ID: 17869503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature.
    Walsh G
    Eur J Pharm Sci; 2002 Mar; 15(2):135-8. PubMed ID: 11849909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant protein production in a variety of Nicotiana hosts: a comparative analysis.
    Conley AJ; Zhu H; Le LC; Jevnikar AM; Lee BH; Brandle JE; Menassa R
    Plant Biotechnol J; 2011 May; 9(4):434-44. PubMed ID: 21040385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opportunities for recombinant antigen and antibody expression in transgenic plants--technology assessment.
    Schillberg S; Twyman RM; Fischer R
    Vaccine; 2005 Mar; 23(15):1764-9. PubMed ID: 15734038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biotechnology and genetic engineering in the new drug development. Part II. Monoclonal antibodies, modern vaccines and gene therapy.
    Stryjewska A; Kiepura K; Librowski T; Lochyński S
    Pharmacol Rep; 2013; 65(5):1086-101. PubMed ID: 24399705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.